ÂÜÀòÂÒÂ×

Sara Isbell has an extensive background in neuroscience, with specific training and expertise in neurodegenerative diseases and conditions, including a recently published paper in drug design and development in Dove Medical Press. Over the course of her 22-year career as she developed novel experiments and consistently contributed to cutting-edge research. This experience was integral to her role as Senior Research Scientist/Co-founder of Research, Raptor Pharmaceuticals Inc., where she was at the helm of the research team, developing and bringing to the market Raptor’s $100 million per year product, Procysbi®, for the ultra-orphan kidney disease, nephropathic cystinosis. In the course of developing Procysbi® for Raptor, Sara and her research team studied a rare class of therapeutic molecules, which, in turn, led to the discovery of neuroprotectant molecules called Captons®. This discovery led to the establishment of Mercaptor Discoveries in 2016.

As Chief Executive Officer, President, Co-Founder & Director of Mercaptor Discoveries, Inc., Sara leveraged her training and experience to develop Captons, including a recent study positive preclinical Proof of Concept (POC) in the Epilepsy Therapy Screening Program (ETSP) run by the National Institutes of Health – National Institute of Neurological Disorders and Stroke (NIH-NINDS). Sara holds a B.S. in Neurochemistry, Biochemistry, Molecular Biology from University of Irvine, Calif.